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ABSTRACT 
 
 
 
 Microparticles encapsulating regenerative medicines have been used in tissue engineering 
because of their several advantages, including non-invasive drug delivery and controllable drug 
release rates.  However, microparticles implanted in tissue defects are readily displaced by 
external mechanical forces, decreasing their regenerative efficacy.  We hypothesized that a drug-
encapsulated colloidal gel formed through colloidal attraction between microparticles would 
resist displacement at an implant site, and subsequently improve therapeutic efficacy.  This 
hypothesis was examined using a colloidal gel formed from the mixing of negatively charged 
microgels composed of poly(ethylene glycol) (PEG) microgels and poly(sodium acrylate), and 
positively charged microgels composed of PEG and poly(vinyl benzyl trimethyl ammonium 
chloride).  The structural strength of the colloidal gel could be tuned with the zeta potential and 
volumetric ratios of the oppositely charged microgels.  Furthermore, the implantation of the 
colloidal gel, encapsulating vascular endothelial growth factor, significantly increased the 
vascular density while limiting host inflammation, as compared with the implantation of unary 
microgel suspensions.  This study demonstrates the enhancement in the efficacy of microparticle 
drug delivery systems by tuning rheological properties of suspensions, which should be useful 
for the design of a wide array of particulate systems for both tissue engineering and drug 
delivery.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1   Micro-particle drug delivery 
Over the past few decades, various nano- and micrometer sized biodegradable polymeric 
particles have been created and used to deliver drug molecules in a controlled and sustained 
manner.
1-3
  These particles allow minimally invasive drug delivery via oral and respiratory 
administration, and intravascular injection.  Overall, particulate-based drug delivery systems 
have significantly enhanced the therapeutic efficacy of drug molecules used for the treatment of 
various diseases and traumas, as demonstrated by a wide array of preclinical and clinical trials.
4,5
   
 
1.2  Drug delivery for tissue engineering 
Particulate systems, encapsulating bioactive macromolecules, have also been explored for 
tissue regenerative therapies.
4,6
  For example, microspheres encapsulating angiogenic growth 
factors or genes have been used to promote capillary formation within large wounds and critical 
tissue defects.
5,7,8
  However, microparticles injected in target tissues were continuously exposed 
to external mechanical deformation, leading to the uncontrollable displacements of particles.
9-11
  
This displacement greatly reduced the concentration of bioactive macromolecules in target 
tissues, resulting in limited tissue regeneration.  Therefore, extensive efforts are being made to 
resolve this challenge while harnessing the advantages of particulate systems, including their 
minimally invasive and controllable drug delivery. 
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1.3  Colloidal gels 
 It is well known that van der Waals or electrostatic attractive forces between colloidal 
particles generate a three dimensionally flocculated elastic network, termed as a colloidal gel.
12-16
 
Recently, a few studies have reported that colloidal gel systems formed from colloidal 
interactions between drug-encapsulating microparticles present the potential to reduce particulate 
loss in target tissues.
17-19
  However, the potential function of a colloidal gel system for improving 
the efficacy of regenerative medicine has currently not been examined through in vivo studies. 
 
1.4  Research Plan 
This study demonstrates that a colloidal gel formed from electrostatic attraction between 
particles improves tissue regeneration using an in vivo model.  Vascular endothelial growth 
factor (VEGF), known to stimulate capillary sprouting, was used as a model regenerative 
medicine.
20-22
.  VEGF was encapsulated into micro-sized hydrogel particles of poly(ethylene 
glycol) diacrylate (PEGDA), termed as PEGDA microgels, through an in situ emulsion 
polymerization.  The PEGDA microgels were modified with negatively or positively charged 
monomers to control zeta potentials and their subsequent interactions between one another.  
Oppositely charged microgels were mixed to form a colloidal gel, and its structural strength was 
modulated through the ratio between oppositely charged microgels, as well as the zeta potential.  
The ability of the colloidal gel system to promote capillary formation was examined in vivo 
using a chicken embryo’s chorioallantoic membrane (CAM).23-25     
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CHAPTER 2 
 
METHODS 
 
2.1  Preparation of microgels  
Microgels were formed through the cross-linking of poly(ethylene glycol) diacrylate 
(PEGDA, MW 400 g/mol, Polysciences) with an ionic monomer.  PEGDA was dissolved in 
deionized (DI) water with a final concentration of 8 % (w/w).  The PEGDA solution was also 
mixed with either (vinylbenzyl)trimethyl ammonium chloride (VTMA, Sigma-Aldrich), a 
cationic monomer, or sodium acrylate (SA, Sigma-Aldrich), an anionic monomer.  The ratio 
(w:w) between PEGDA and VTMA was varied from 1:0 to 2:5 and the ratio (w:w) between 
PEGDA and SA was varied from 1:0 to 4:5.  The pregelled solution also contained 0.1 M 
ammonium persulfate (APS, Sigma-Aldrich) and 1 % (w/w) poly(vinyl alcohol) (PVA, Sigma-
Aldrich).  The solutions were sterilized through filtration using 0.22-µm nylon filters (Millex).  
The sterile polymer solution was added to dichloromethane (DCM, Sigma-Aldrich) containing a 
catalyst N,N,N’,N’-tetramethylethylenediamine (TEMED, Fluka) at a concentration of 3.3×10-5 
M.  Following the addition, the solvent mixture was immediately vortexed for 30 seconds to 
emulsify the solution and polymerize the particles.  The volumetric ratio between the solvent and 
polymer solution was kept constant at 3:1.  Following the in situ emulsification and 
polymerization, DCM was removed by repeated centrifugation and washings with sterile 
phosphate buffer saline (PBS) pH 7.4 (Invitrogen).  They were both reconstituted to a 
concentration of ~2.5 % (w/w), respectively, quantified through measurements of solution and 
dry solid mass.  
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2.2  Encapsulation of biomacromolecules in microgels  
 Bovine serum albumin (BSA, Sigma-Aldrich) or vascular endothelial growth factor 
(VEGF, R&D Systems) were encapsulated in microgels at a concentration of 50 mg/mL and 20 
ng/mL, respectively.  The BSA or VEGF were mixed with the pre-gelled solution containing 
APS and PVA.  The mixture was added to DCM containing TEMED followed by vortexation 
and in situ polymerization as described above.  The DCM was also removed following the same 
procedure as described above. 
 
2.3  Measurements of zeta potential and particle size 
 Zeta potentials and diameters of the PEGDA and VTMA microgels, termed as PVTMA 
microgels, and those of PEGDA and SA microgels, termed as PSA microgels, were measured 
using a 3000HSa Zetasizer (Malvern Instruments).  First, 100 µL of microgels in PBS were 
diluted with 3 mL DI water.   Next, the diluted microgel suspensions were loaded in the zetasizer 
chamber, and the zeta potential and microgel diameters were calculated according to particulate 
mobility and dynamic light scattering measurements. 
 
2.4  Preparation of a colloidal gel 
 PVTMA and PSA microgels were mixed, varying the volumetric ratios between the 
suspensions:  1:0, 5:1, 2:1, 1:1, 0.5:1, and 0:1, respectively.  The ionic polymer concentrations of 
the microgels were kept at 20 % (w/w) VTMA and 10 % (w/w) SA for the PVTMA and PSA 
microgels, respectively.  The mixtures were vortexed for one to two seconds to ensure 
homogeneous mixing.  VEGF-encapsulated microgel suspensions were also mixed using the 
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same method to prepare proangiogenic colloidal gels.  Mixtures of PVTMA and PSA microgels 
were imaged using a Scanning Electron Microscope (6060LV SEM, JEOL).  First, the microgel 
mixtures were diluted by adding 15 mL DI water to 500µL of the colloidal samples.  Next, 50 µL 
of the diluted samples were placed on silicon wafers and flash frozen using liquid nitrogen.  The 
frozen samples were freeze dried using a lyophilizer (Freezezone 6, Labconco).  The samples 
were imaged at an electron intensity of 30kV. 
 
2.5  Rheological characterization of colloidal gels  
 The rheological properties of the PVTMA and PSA microgel mixtures were characterized 
using a low amplitude oscillatory shear measurement.  The samples were loaded between two 
parallel plates of a rheometer (Bohlin, CD-50).  Subsequently, the samples were oscillated at a 
stress of 1.1 Pa, while varying the frequency from 1 to 6 Hz.   The elastic modulus and loss 
modulus of the microgel mixtures, at varied frequencies, were recorded to evaluate stiffness and 
viscoelasticity.  The rheological properties of the unary suspensions of PVTMA microgels and 
PSA microgels were also tested following the same procedure.  
 
2.6  Measurements of biomacromolecule release rates 
 Drug release profiles of the microgels were characterized by measuring the amount of 
BSA released from the microgels over time.  Samples were placed in separate 15 mL conical 
tubes (Fisherbrand) with 4mL of PBS (Invitrogen), as a release buffer.  The samples were 
incubated at 37 
o
C over a 7 day period, under sterile conditions.  The PBS was collected and 
replaced with fresh release buffer at 0, 0.3, 1, 3, 6, 18, 28, 50, 98, and 170 hours.  The collected 
buffers were stored at -20ºC until analysis. 
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 The concentrations of BSA in the collected PBS samples were measured using a 
Bicinchoninic Acid Protein Assay Kit (Thermo Scientific).  First, a series of solutions containing 
known concentrations of BSA were prepared as standards.  Using a UV spectrophotometer 
(Synergy HT, BioTek), the absorbance of the standards, samples, and controls containing DI 
water, were measured at 562 nm.  The absorbencies of the controls were subtracted from those of 
the PBS samples and standards.  A standard calibration curve was developed to relate the 
concentration of BSA to its observed absorbance, from which the concentrations of BSA 
released were determined.  Drug release profiles were also determined for VEGF using the same 
aforementioned procedure and VEGF encapsulating concentrations, and were analyzed using a 
VEGF ELISA kit (R&D Systems). 
 
2.7  Chorioallantoic membrane assay 
 Fertilized chicken eggs (Hy-Line W-36) were obtained from the University of Illinois 
Poultry Farm (Urbana, IL).  The eggs were initially incubated for 7 days, while being placed 
horizontally inside an incubator at 37 ºC and 65 % humidity.  After the initial incubation period, 
a hole with a diameter of 2 cm was made in the top of the egg shell by carefully removing shell 
fragments.  The hole on the egg shells were covered with tape (Scotch) and incubated at 37 ºC 
overnight to ensure survival after the initial shell opening. 
 Next, 100 µL microgel samples were placed on the CAM of individual embryos.  
Microgel samples, both encapsulating VEGF and without VEGF, were examined with the 
following compositions:  PVTMA suspension, PSA suspension, and mixture of 2:1 (v/v) PSA 
and PVTMA suspension.  The openings were covered with tape and the eggs were incubated at 
37 ºC.  Images of the CAMs were taken at the initial insertion of samples, after 1 day, 5 days, 
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and 10 days using a S6E stereomicroscope (Leica) linked with D-Lux E Camera (Leica).  All 
CAM assays were performed under sterile conditions. 
 
2.8  Quantitative analysis of microgel retention ratio 
 Images of CAM samples from the initial sample implantation and 1 day after 
implantation were examined to determine the microgel retention ratio.  The retention ratio, 
defined as the microgel suspension area on the CAM after one day to the initial implantation 
area, was determined using analytical software (ImageJ, free software available from NIH).  
Additionally, microgel mixtures with varied mixing ratios and embedded blue dyed Polybeads® 
(Polysciences) were implanted on CAMs.  The retention of microgel particles at the implant site 
over six days was examined and analyzed using ImageJ. 
 
2.9  Analysis of CAM inflammation and capillary formation 
 The CAM cross-sections were examined through histological analysis.  On the 10th day 
after implantation, embryos were fixed with a 10 % neutral buffered formalin (NBF) solution (4 
% formaldehyde, Sigma-Aldrich).  After 24 hours of fixation, a 1 cm x 1 cm CAM tissue sample 
at the location of sample insertion was cut using suture scissors.  The samples were then 
processed for paraffin embedding, sectioning, and histological staining.  Standard protocols of 
hematoxylin and eosin (H&E) and α-smooth muscle actin (αSMA) staining were used to 
examine the presence of inflammation and quantify blood vessel formation, respectively.  
 CAM tissue samples, stained with a standard H&E, were examined to assess immune 
response.  For each sample group, cross sectional images at the implant site (IMS) and a remote 
site (RES), 3 mm away from the IMS, were taken using a DMIL inverted microscope (Leica) 
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linked with a D-Lux E camera (Leica).  The IMS was specified by marking the center of the 
implanted microgels using image processing software (Image J).  Then, the RES site was 
identified by measuring 3 mm away from the IMS on the CAM cross-sections.  The 
inflammatory response was assessed by quantifying the area of inflammation determined by 
immune cells and fibrotic tissue, distinguishable through H&E staining, over the entire area 
examined.  The inflammatory areas and overall areas were determined using analytical software 
(ImageJ).  The average degree of inflammation, the ratio between inflammatory area and overall 
area, was calculated for each sample group. 
 CAM cross-sections were also stained for αSMA to quantify mature capillary blood 
vessel densities.  The numbers of positively stained blood vessels were counted for cross-
sections at the IMS and RES, and averaged over the area examined.  ImageJ software was used 
for vessel analysis, and the average blood vessel density was calculated for each sample group. 
 One-Way Analysis of Variance (ANOVA) was used to determine the statistical 
significance of the histological data.  The Scheffe Post Hoc test was applied to all pair-wise 
differences between means.  Data was considered significant for p values < 0.05.  
  
9 
 
CHAPTER 3 
 
RESULTS 
 
3.1  Preparation and characterization of colloidal microgels 
 The microgels consisting of PEGDA and SA (PSA microgels), and those of PEGDA and 
VTMA (PVTMA microgels), were separately prepared through an in situ emulsion 
polymerization.  The sign and magnitude of the zeta potentials were controlled by the type and 
concentration of ionic unit incorporated into the microgel, respectively (Figure 1A).  The 
concentrations of the ionic units had relatively no effect on the average microgel size; however, 
the PSA microgels had a slightly larger diameter compared to PVTMA particles (Table 1, Figure 
1C).  The microgel yield, determined though the evaporation of the remaining aqueous and 
organic solutions was slightly higher for the PVTMA microgels compared to the PSA microgels 
(Table 2).  The VEGF exposed to the APS and TEMED, during encapsulation, was not denatured 
as confirmed with the same conformational peak as fresh VEGF (Figure 1A). 
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 The PSA microgels with a zeta potential of -20 mV and the PVTMA microgels with a 
zeta potential of 35 mV were mixed together to prepare a colloidal gel (Figure 2A).  
Interestingly, mixing liquid-like PSA and PVTMA suspensions at an equivalent volumetric ratio 
Table 1:  Hydrodynamic diameter and polydispersity of the PSA and PVTMA microgels. 
 
Monomer Mass Fraction Diameter (nm) Polydispersity 
10% SA 733.8  ±   67.3 0.29 ± 0.15 
10% VTMA 601.3  ±   56.5 0.29 ± 0.11 
20% VTMA 616.4  ± 222.0 0.38 ± 0.10 
 
(A)       (B) 
 
(C) 
 
Figure 1:  (A) Zeta potentials of negatively charged PSA microgels () and positively charged PVTMA 
microgels ().  (B) Circular dichromism for VEGF in a radical polymerizing environment, containing initiator 
and catalyst, (─) was similar to VEGF controls in buffered solution (─).  (C)  SEM images of the PSA-
PVTMA mixture having a volumetric ratio of 2:1 for the PSA and PVTMA microgels, respectively. 
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instantly resulted in a solid material, which resisted flow under the force of gravity (Figure 2B).  
The solid structure was maintained unless disturbed by external mechanical force.  No 
sedimentation was observed for the mixture of PSA and PVTMA microgels.  Additionally, PEG 
microgels mixed with PSA or PVTMA microgels did not form a solid structure and flowed to the 
bottom of vials (Figure 2B). 
 
 
 
 Viscoelastic properties of the PSA suspension, PVTMA suspension and the mixture of 
both were further characterized with a low-amplitude oscillatory shear measurement.  As 
expected, at any given frequency, the mixture of PSA and PVTMA suspensions (PSA-PVTMA 
mixture) presented a higher storage modulus compared to the unary PSA or PVTMA 
suspensions by one order of magnitude (Figure 3A).  The dependency constant of the storage 
modulus on frequency, , was calculated by fitting the modulus  with respect to frequency 
( ) on a log scale to a linear curve using Equation (1) 
(A)               (B) 
 
Figure 2:  (A) Schematic of the colloidal gel formation upon mixing of PSA and PVTMA unary suspensions.  
(B) The mixture of PSA and PVTMA particles (1:1) resulted in a colloidal gel that resisted flow under 
gravitational forces, while pure PEG particles, mixtures of PEG and PSA (1:1), and PEG and PVTMA (1:1), 
succumbed to flow. 
 
(Vinylbenzyl) trimethyl-
ammonium chloride 
N+
CH3
CH3
CH3
Cl-
O
O-
Na
+
Sodium Acrylate
PEGDA + Microgel Suspension Colloidal Gel
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                    (1) 
where,  is the modulus at zero frequency.  The dependency of  on the frequency was the 
smallest for the PSA-PVTMA mixture compared to the unary suspensions (Table 2).   
 
 
 
 
 The storage modulus of the PSA-PVTMA mixture was further tuned with the volumetric 
ratio between PSA and PVTMA microgels.  Interestingly, the maximum storage modulus was 
Table 2.  Storage modulus dependencies ( ), initial BSA burst rate constant ( 1), subsequent BSA 
release rate constant ( 2), microgel retention level, BSA loading efficiency, and microgel yield for PSA 
and PVTMA suspensions, and a mixture of both (2-1 mixture). 
 
Microgels Storage Mod. 
Dependency, α 
Initial Burst, 
β1 (hr
-1
) 
Remaining 
Release, β2 (hr
-1
) 
Retention level 
(mm
2
/mm
2
) 
BSA Loading 
Efficiency  
Microgel Yield 
PSA 0.6226  0.3263  0.0072 1.00 ± 0.57 0.0687 ± 0.013 0.845 ± 0.163 
PVTMA 0.0078  0.1247 0.0089         ∞  0.1072 ± 0.035 0.155 ± 0.071 
Mixture 0.0032  0.3552 0.0222 2.49 ± 0.94 0.0844 ± 0.023 ─ 
 
(A)         (B) 
 
Figure 3:.  (A) The PSA-PVTMA mixture ()  presented the highest storage modulus with the smallest 
dependency on frequency compared to unary suspensions of PSA () or PVTMA ().  The samples in this 
experiment were oscillated at varied frequencies, while maintaining a constant shear stress of 1.13 Pa.  (B) 
The storage moduli () and interparticle energies () of the PSA-PVTMA mixtures were tuned with the 
volumetric ratio between PSA and PVTMA microgels.  In (B), the storage modulus values were measured 
by oscillating samples at 1 Hz.  The shear stress applied was kept constant at 1.13 Pa. 
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attained when the volumetric ratio between the PSA and PVTMA microgels was 2:1 (Figure 
3B).  The storage moduli were further converted to interparticle energies between the microgels 
using Equation (2), so that the inter-microgel forces are described in a quantitative manner 
     (2) 
where,  is the radius of the particle,  is the interparticle distance to reach the primary energy 
minimum, and  is the particle volume fraction [15].  The attractive interparticle energy, , 
of the PSA-PVTMA mixture with a volumetric ratio of 2:1 was three times larger than the unary 
suspensions.  As a result, PSA-PVTMA mixtures with a volumetric ratio of 2:1 were used in the 
proceeding in vitro and in vivo studies. 
  
3.2   In vitro bovine serum albumin (BSA) release study 
 The BSA release rate for the PSA-PVTMA mixture was compared to those of the unary 
suspensions in vitro.  During incubation of the microgels, there was an initial BSA burst during 
the first 6 hours, independent of microgel compositions (Figure 4A), followed by a slower BSA 
release over five to seven days (Figure 4B).  The BSA release profile for the first 6 hours of 
incubation and thereafter were separately fitted to a first-order drug release kinetics 
approximation using Equation (3) 
      (3) 
where,  is the concentration of BSA remaining in the microgels,  is the initial amount 
of BSA encapsulated,  is the incubation period, and  is the BSA release rate constant (hr
-1
).  
There was not a significant difference between the BSA release profiles for the PSA and 
PVTMA microgel suspensions, although the release rate was slightly higher for the PSA 
microgels (Figure 4A and Table 2).  Additionally, the BSA release profile for the PSA-PVTMA 
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mixture was comparable to that of the PSA suspension.  The BSA loading efficiency for PSA 
microgels was similar to that of the PVTMA microgels (Table 2). The BSA loading efficiency 
for PSA microgels was similar to that of the PVTMA microgels (Table 2).  Release profiles of 
VEGF from microgel particles were also examined.  Similar to BSA release profiles, the VEGF 
release rate was not significantly dependent on the microgel composition and the formation of a 
colloidal gel (Figure 4B). 
 
 
 
3.3  In vivo evaluation of the microgel retention level 
 The microgel retention level for the PSA-PVTMA mixture, at the implant site, was 
compared with the individual PSA and PVTMA suspensions using a CAM assay.  One day after 
the implantation of samples on CAMs, the PSA and PVTMA microgels were partially or 
(A)     (B) 
        
Figure 4:  (A) Release profiles of bovine serum albumin from the PSA suspension (), PVTMA 
suspension () and the mixture of both suspension () were comparable to each other. The initial 
burst profile monitored during the first 6 hours of incubation (top), and the BSA release profile 
monitored over a 7 days period (bottom) are represented.  The volumetric ratio between the PSA and 
PVTMA was 2:1 for the mixture. (B) Release profiles of VEGF for PSA suspension (), PVTMA 
suspension () and the mixture of both suspensions () were comparable to each other over a 7 
days period.  The volumetric ratio between the PSA and PVTMA was 2:1 for the mixture. 
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completely displaced throughout the CAM.  In contrast, a significant fraction of the microgels in 
the PSA-PVTMA mixture remained at the implant site (Figure 5A).  The microgel retention level 
was quantified by the tissue area covered by the microgel at Day 1 to that instantly after 
implantation (Day 0).  The microgel retention level for the PSA-PVTMA mixture was over twice 
as large compared to the PSA suspension (Table 2).  Additionally, the PSA-PVTMA mixtures 
(2-1 mixing ratio) were found at the implant site after Day 6, a period over which the majority of 
the drug is released.  In contrast, unary suspensions and PSA-PVTMA with non-optimal mixing 
ratios were not visible (Figure 5B).  Therefore, the unary PSA or PVTMA suspensions and 
mixture of PSA and PVTMA prepared at a ratio of 1:3 readily succumbed to flow due to a 
limited degree of flocculation between microgels. 
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(A)                    
    
(B) 
 
Figure 5:  (A) The PSA suspensions placed on the CAMs were mostly lost after one day of 
implantation (top).  The PVTMA suspensions placed on the CAMs were totally lost after one day of 
implantation (middle).   In contrast, a significant volume of the PSA-PVTMA mixture remained on the 
CAM after one day of incubation (bottom).  In (A), the left photos were taken after sample implantation 
and the right photos were taken after one day of incubation.  The dashed circles represent the PSA 
suspension and the PSA-PVTMA mixture remaining on the CAM, respectively.  (B)  The PSA 
suspensions placed on the CAMs were lost after six days of implantation, while the PSA-PVTMA 
mixture remained on the CAM after six days of incubation.  The volumetric ratio between the PSA and 
PVTMA was 2:1 for the mixture for both (A) and (B).  In (B), the left photos were taken after sample 
implantation and the right photos were taken after six days of incubation. 
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3.4  In vivo evaluation of inflammation and capillary formation 
The liquid-like PSA and PVTMA suspensions and the solid-like PSA-PVTMA mixture 
were implanted on CAMs to examine the effects of their rheological properties on host 
inflammatory response.  The inflammatory area at both implant site and remote site (i.e., tissue 3 
mm away from the implant site) were quantified using H&E stained tissue sections (Figure 5B); 
however, chicken embryos with implanted PVTMA microgels died after a few days of 
incubation and could not be examined. 
  The PSA microgel implant stimulated a mild inflammation, represented by transparent 
fibrous tissue (Figure 6A).  The degree of inflammation, defined as the fraction of the 
inflammatory tissue area was higher at the implant site as compared with the remote site.  There 
was no significant difference between the degrees of inflammation related to the implant 
composition (Figure 6A). In contrast, the degree of inflammation for the VEGF-encapsulated 
microgels had a dependency on the implants’ rheological properties.  The implantation of VEGF-
encapsulated PSA microgels significantly stimulated host inflammation compared to the VEGF-
free PSA suspension, as confirmed with a larger white scar tissue formed at the implantation site 
and an increased degree of inflammation (Figure 6A).  On the other hand, the implantation of the 
VEGF-encapsulated PSA-PVTMA mixture limited an increase in the degree of inflammation 
induced by VEGF (Figure 6A & 6B).   
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(A)          
 
(B) 
 
 
Figure 6:  (A) The VEGF-encapsulating PSA microgels implanted on CAMs stimulated a larger area of 
inflammatory tissue compared to the VEGF-free PSA suspension a) within five days of incubation.  The 
implantation of the VEGF-encapsulated PSA-PVTMA mixture d) led to a small area of inflammatory 
tissue, similar to the VEGF-free PSA-PVTMA mixture b).  The volumetric ratio between the PSA and 
PVTMA microgels in the mixture was 2:1. In a), b), c) and d), the photos in the first column were taken 
right after sample implantation those in the second columns were taken after five days of incubation.  e) 
The quantitative analysis of the degree of inflammation was mediated by both VEGF and the implant 
composition. * indicates statistical significance relative to control conditions with no implantation (p < 
0.05).  (B) a) CAM cross-sections at the implant site and the remote site (i.e., 3 mm away from the 
implant site) were H&E stained to examine the inflammatory response.  The implantation of the VEGF-
encapsulated  PSA-PVTMA mixture limited the inflammatory response induced by VEGF (c) compared to 
the unary suspension of VEGF-encapsulating PSA microgel (b).  In (b) and (c), the left images represent 
the CAM at the implant site, and the right images represent the CAM at the remote site. The volumetric 
ratio between the PSA and PVTMA microgels in the mixture was 2:1. 
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 The VEGF-encapsulated microgels also stimulated capillary vessel formation at the 
implant site, with its efficacy mediated by the rheological properties of the implants (Figure 7A).  
Specifically, the mature capillary density, determined through αSMA staining, was twice as large 
at the implant site for the VEGF-encapsulated PSA suspension compared to controls.  The 
implantation of the PSA-PVTMA mixture resulted in a three fold increase in capillary density at 
both implantation site and remote sites (Figure 7A).  The PSA-PVTMA mixture also led to the 
formation of capillary vessels with larger diameters (Figure 7A).  The proangiogenic index, 
defined by the ratio of vascular density to the degree of inflammation, was significantly larger 
for the PSA-PVTMA mixture encapsulating VEGF compared to the unary PSA suspension 
encapsulating VEGF (Figure 7B).  Specifically, there was over a three-fold increase in the 
proangiogenic index for the mixture at the implant site, and nearly a two-fold increase at the 
remote site.  
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(A)      
 
(B) 
 
Figure 7:  (A) a) CAM cross-sections at the implant site and the remote site (i.e., 3 mm away from the 
implant site) were stained with α smooth muscle actin (α-SMA) antibody to identify mature blood 
vessels.  The implantation of the 2:1 PSA-PVTMA mixture led to an increase in the density and size 
of mature blood vessels c) compared to the unary suspension of VEGF-encapsulated PSA microgels 
b).   In b) and c), the left images represent the CAM at the implant site, and the right images represent 
the CAM at the remote site.  Quantitative analysis of the vascular density confirmed that the mixture 
of PSA and PVTMA suspensions increased the vascular density more significantly than the PSA 
suspension at both implant site and remote site. The volumetric ratio between the PSA and PVTMA 
microgels in the mixture was 2:1.  * indicates statistical significance relative to control conditions with 
no implantation (p < 0.05). (B)  The proangiogenic index for CAM cross-sections implanted with the 
PSA-PVTMA mixture or the PSA suspension.  The volumetric ratio between the PSA and PVTMA 
microgels in the mixture was 2:1.  Microgels used in both conditions encapsulated VEGF.  * indicates 
statistical significance relative to the values between the PSA+VEGF and the Mixture + VEGF 
samples for their respective sites (p < 0.05). 
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CHAPTER 4 
 
DISCUSSION 
 
The results of this study demonstrates that a colloidal gel, formed from the mixing of 
oppositely charged PSA and PVTMA microgels, significantly enhances the proangiogenic 
efficacy of VEGF-encapsulated microgels.  The rheological properties of the PSA-PVTMA 
mixture were controlled through zeta potentials of microgels and also the volumetric ratio 
between PSA and PVTMA microgels, as correlated with changes in the magnitude of attractive 
interparticle energy.  The PSA-PVTMA mixture implanted on CAMs presented enhanced 
microgel retention levels compared to the implantation of individual PSA or PVTMA 
suspensions.  The implantation of the VEGF-encapsulated colloidal gels also resulted in a lower 
degree of inflammation and a larger density of mature capillaries than the individual PSA or 
PVTMA suspensions.   
 The zeta potentials of the microgels were controlled by incorporating varied amounts of 
charged monomers, SA and VTMA, into the PEGDA microgel.  The unary suspensions 
presented liquid-like rheological properties due to electrostatic repulsion between microgels with 
charges of the same sign.  In contrast, the PSA-PVTMA mixture presented a higher storage 
modulus than the unary suspensions, and an independency of storage modulus on frequency, .  
Both the higher storage modulus and the lower  value confirm that PSA and PVTMA microgels 
were electrostatically attracted to generate a three-dimensionally flocculated elastic network.
15,19
  
Since the Hamaker constants for PSA, PVTMA, and water (~10
-20 
J) are similar to each other, it 
is not likely that van der Waals forces are significantly involved in the formation of the colloidal 
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gel.  In addition, the storage modulus and interparticle energy, regulated with the ratio between 
PSA and PVTMA microgels, are likely related to the changes in the number of microgels 
assembled by electrostatic repulsion and that assembled by electrostatic attraction.   
Both PSA and PVTMA microgels released protein molecules, mostly via diffusion, as 
confirmed with first-order drug release kinetics.  Comparable protein release profiles of PSA and 
PVTMA microgels, as demonstrated by microgels loaded with both BSA and VEGF, implied 
that the protein release was governed by microgel mesh size rather than the interaction between 
the microgel and protein.  In addition, minimal deviations between protein release profiles of the 
PSA or PVTMA suspension and PSA-PVTMA mixture confirmed that the flocculated structure 
did not affect the protein transport through the colloidal gel, unlike polymeric hydrogel systems 
with nanometer-sized pores.  Therefore, the protein release rate may be readily tuned by 
engineering microgel degradation rates and incorporating protein-binding cues into the 
microgels, as extensively demonstrated in drug delivery studies.
26-28
  These microgel-based 
systems present a distinct advantage over bulk hydrogel systems because of their controllable 
and well defined drug release rates. 
The higher storage modulus of the PSA-PVTMA mixture, compared to the unary 
suspensions, further improved the microgel retention level at the implant site as demonstrated 
with the in vivo CAM assay.  The implant site on the CAM is subject to dynamic mechanical 
loading exerted by the heart beat of the chicken embryo.  Therefore, the unary suspensions and 
PSA-PVTMA mixtures with non-optimal volumetric mixing ratios for a fully developed 
cohesive energy readily succumbed to flow due to an absence of a flocculated structure between 
microgels.  In contrast, the three dimensionally flocculated structure of the PSA-PVTMA 
mixture (2-1 vol. ratio) likely provided a significantly higher resistance against flow.  The loss of 
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microgels from this PSA-PVTMA mixture may further be reduced by tuning the storage 
modulus of the mixture with the concentration, size and size distribution of microgels. 
Implantation of the VEGF-encapsulated PSA-PVTMA mixtures on CAMs significantly 
reduced the degree of host inflammation as compared to the PSA suspension.  We propose that 
the severe inflammation resulting from the implantation of the unary suspension should be 
related to the displacement of microgels secreting VEGF.  It is likely that microgels and VEGF 
do not individually stimulate severe inflammation, as shown with the implantation of blank 
microgels and also with a previous study testing bolus administration of VEGF.
29
  However, it is 
likely that the displaced microgels releasing VEGF acted as a macro-sized antigen to amplify the 
immune response in a synergistic manner.  In contrast, the PSA-PVTMA mixture with the higher 
microgel retention level likely decreased the degree of inflammation by limiting particulate 
displacement.  It is likely that the cationic PVTMA microgels stimulated a more severe 
inflammatory response than the anionic PSA microgels, and the underlying mechanism will be 
examined in future studies.   
 The VEGF-encapsulated PSA-PVTMA mixture also increased the density of mature 
vessels (i.e., arterioles) as compared with the implantation of the unary suspensions.  We suggest 
that severe inflammation resulting from the administration of the unary suspensions denatured 
exogenous VEGF and also other endogenous growth factors critical for the formation of 
arterioles, such as angiopoietin-1 and platelet-derived growth factor.
20-22
  In contrast, the PSA-
PVTMA mixture had a lower level of microgel displacement and inflammatory response, which 
increased the dose of VEGF, effectively stimulating angiogenesis at the implant site.  In addition, 
the PSA-PVTMA mixture likely prevented the denaturation of host endogenous factors critical 
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for forming mature blood vessels, as confirmed with a larger density of arterioles containing 
smooth muscle layers.   
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CHAPTER 5 
 
CONCLUSION 
 
 Overall, this study successfully demonstrated that a colloidal gel, formed from 
interparticle flocculation, improved the proangiogenic efficacy of VEGF-encapsulated microgels.  
The rheological properties of the colloidal gel were readily tuned with the zeta potential and the 
volumetric ratio between oppositely charged microgels, which changed the interparticle energy 
and subsequent degree of flocculation.  The limited host inflammation and enhanced 
neovascularization from using a colloidal gel as a proangiogenic factor releasing device was 
related to a higher microgel retention level at the implant site.  The physical properties and 
functionality of the colloidal gel can further be improved with several intrinsic and extrinsic 
variables that alter interparticle energy.  The design principles of such a colloidal gel system will 
readily be extended to a broad array of microparticles that release drug molecules in a sustained 
manner.  The colloidal gel system presented in this study would significantly enhance the 
efficacy of microparticle-based drug delivery strategies in tissue engineering, while maintaining 
their injectability and drug release profiles.  
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